IDYA
Price
$43.38
Change
+$0.29 (+0.67%)
Updated
May 7, 10:45 AM EST
Earnings call today
YMAB
Price
$17.23
Change
-$0.00 (-0.00%)
Updated
May 7, 11:10 AM EST
Earnings call today
Ad is loading...

IDYA vs YMAB

Header iconIDYA vs YMAB Comparison
Open Charts IDYA vs YMABBanner chart's image
IDEAYA Biosciences
Price$43.38
Change+$0.29 (+0.67%)
Volume$100
CapitalizationN/A
Y-mAbs Therapeutics
Price$17.23
Change-$0.00 (-0.00%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
IDYA vs YMAB Comparison Chart

Loading...

IDYADaily Signal changed days agoGain/Loss if shorted
 
Show more...
YMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
IDYA vs. YMAB commentary
May 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and YMAB is a Hold.

COMPARISON
Comparison
May 07, 2024
Stock price -- (IDYA: $41.03 vs. YMAB: $9.38)
Brand notoriety: IDYA and YMAB are both not notable
Both companies represent the Biotechnology industry
Market capitalization -- IDYA: $3.22B vs. YMAB: $756.36M
IDYA [@Biotechnology] is valued at $3.22B. YMAB’s [@Biotechnology] market capitalization is $756.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $547.77B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both IDYA and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 3 bearish.
  • YMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than YMAB.

Price Growth

IDYA (@Biotechnology) experienced а +3.25% price change this week, while YMAB (@Biotechnology) price change was -2.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.04%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +71.93%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2024.

YMAB is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+4.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for IDYA with price predictions.
OPEN
A.I.dvisor published
a Summary for YMAB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
IDYA($3.22B) has a higher market cap than YMAB($756M). YMAB YTD gains are higher at: 151.466 vs. IDYA (18.550).
IDYAYMABIDYA / YMAB
Capitalization3.22B756M426%
EBITDAN/AN/A-
Gain YTD18.550151.46612%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
IDYAYMAB
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
76%
Bearish Trend 12 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
IDYADaily Signal changed days agoGain/Loss if shorted
 
Show more...
YMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RERBX54.980.41
+0.75%
American Funds Europacific Growth R2
VGISX30.920.23
+0.75%
Virtus Duff & Phelps Glb Rl Estt Secs I
RLNCX42.610.30
+0.71%
Russell Inv International Devd Mkts C
IUTCX25.790.10
+0.39%
Invesco Dividend Income C
AGEAX11.380.01
+0.09%
Water Island Event-Driven Fund A

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+1.66%
GRI - IDYA
54%
Loosely correlated
-4.43%
INAB - IDYA
47%
Loosely correlated
-1.96%
SNDX - IDYA
39%
Loosely correlated
+0.87%
YMAB - IDYA
38%
Loosely correlated
-0.58%
TNGX - IDYA
36%
Loosely correlated
+0.26%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ZYME. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-0.58%
ZYME - YMAB
43%
Loosely correlated
+2.22%
IDYA - YMAB
39%
Loosely correlated
+1.66%
SRRK - YMAB
36%
Loosely correlated
+1.66%
TCRX - YMAB
36%
Loosely correlated
-1.04%
SWTX - YMAB
34%
Loosely correlated
+4.06%
More